Steven Mark Sorscher, MD
- Professor, Hematology and Oncology

Steven Mark Sorscher, MD
- Education
- BS, Yale University, 1981
- MD, University of Michigan - Ann Arbor, 1985
- Residency
- Internal Medicine, University Michigan Affiliated Hospitals, 1988
- Fellowship
- Hematology And Oncology, University of California - San Diego, 1991
- Board Certifications
- American Board of Internal Medicine, Internal Medicine
- American Board of Internal Medicine, Medical Oncology
- Positions
- Professor, Hematology and Oncology
- Departments and Affiliations
- Hematology and Oncology
- Comprehensive Cancer Center
Research
- Rationale for evaluating breast cancers of Lynch syndrome patients for mismatch repair gene expression. Sorscher S. Breast Cancer Res. Treat. 2019 Nov; 178(2):469-471.
- Molecular Markers of Molecular Markers. Sorscher S. J. Clin. Oncol. 2019 09; 37(25):2291.
- Quantitative mRNA Expression Assays and Synchronous Breast Cancers: A Case Report. Sorscher S. . ; 12(2):418-420.
- Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer. Amin M, Desai M, Trinkaus K, Brown A, Wang-Gillam A, Tan B, Picus J, Sorscher S, Highkin M, Lears K, Lockhart AC. . 2019 Jun; 10(3):412-420.
- Circulating cell-free DNA use for diagnosing cholangiocarcinoma. Sorscher S. Clin Epigenetics. 2019 05; 11(1):75.